Zacks Research Issues Negative Outlook for Novavax Earnings

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Analysts at Zacks Research cut their FY2027 EPS estimates for shares of Novavax in a research report issued on Monday, April 14th. Zacks Research analyst S. Ganoria now forecasts that the biopharmaceutical company will post earnings per share of $0.51 for the year, down from their previous forecast of $0.54. The consensus estimate for Novavax's current full-year earnings is ($1.46) per share.

Several other analysts also recently weighed in on NVAX. BTIG Research assumed coverage on shares of Novavax in a research report on Friday, February 28th. They set a "buy" rating and a $19.00 target price on the stock. TD Cowen raised Novavax to a "hold" rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, Novavax presently has a consensus rating of "Hold" and an average price target of $18.00.

Novavax Price Performance

Novavax stock traded down $0.20 during midday trading on Wednesday, reaching $6.00. The company's stock had a trading volume of 4,866,614 shares, compared to its average volume of 8,240,446. Novavax has a 52-week low of $3.86 and a 52-week high of $23.86. The stock has a market capitalization of $965.06 million, a P/E ratio of -2.65, a PEG ratio of 2.85 and a beta of 3.15. The stock's 50-day simple moving average is $7.27 and its 200-day simple moving average is $8.63.

Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to analysts' expectations of $85.48 million. During the same quarter in the prior year, the business posted ($1.44) earnings per share.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new position in shares of Novavax during the fourth quarter valued at approximately $27,000. Spire Wealth Management purchased a new position in shares of Novavax during the 4th quarter worth $29,000. New Age Alpha Advisors LLC acquired a new stake in shares of Novavax during the fourth quarter valued at about $35,000. KBC Group NV raised its position in Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 3,917 shares during the period. Finally, TigerOak Management L.L.C. acquired a new position in Novavax during the 4th quarter worth about $86,000. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.